RU2013113752A - Фармацевтическая композиция - Google Patents
Фармацевтическая композиция Download PDFInfo
- Publication number
- RU2013113752A RU2013113752A RU2013113752/15A RU2013113752A RU2013113752A RU 2013113752 A RU2013113752 A RU 2013113752A RU 2013113752/15 A RU2013113752/15 A RU 2013113752/15A RU 2013113752 A RU2013113752 A RU 2013113752A RU 2013113752 A RU2013113752 A RU 2013113752A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- particles
- sodium
- surfactant
- particle size
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- 239000000203 mixture Substances 0.000 claims abstract 29
- 239000002245 particle Substances 0.000 claims abstract 22
- -1 polyoxyethylene Chemical class 0.000 claims abstract 10
- 239000004094 surface-active agent Substances 0.000 claims abstract 10
- 229920000642 polymer Polymers 0.000 claims abstract 8
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims abstract 6
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims abstract 6
- 239000002562 thickening agent Substances 0.000 claims abstract 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract 5
- 239000003381 stabilizer Substances 0.000 claims abstract 5
- 229920002675 Polyoxyl Polymers 0.000 claims abstract 4
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims abstract 4
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims abstract 4
- 229960003040 rifaximin Drugs 0.000 claims abstract 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims abstract 3
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical class CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract 2
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract 2
- 150000001298 alcohols Polymers 0.000 claims abstract 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims abstract 2
- 239000003945 anionic surfactant Substances 0.000 claims abstract 2
- 239000003833 bile salt Substances 0.000 claims abstract 2
- 229940093761 bile salts Drugs 0.000 claims abstract 2
- 150000007942 carboxylates Chemical class 0.000 claims abstract 2
- 239000004359 castor oil Substances 0.000 claims abstract 2
- 235000019438 castor oil Nutrition 0.000 claims abstract 2
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims abstract 2
- 229960000878 docusate sodium Drugs 0.000 claims abstract 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract 2
- 235000010445 lecithin Nutrition 0.000 claims abstract 2
- 239000000787 lecithin Substances 0.000 claims abstract 2
- 229940067606 lecithin Drugs 0.000 claims abstract 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims abstract 2
- 229920000847 nonoxynol Polymers 0.000 claims abstract 2
- 229920002113 octoxynol Polymers 0.000 claims abstract 2
- 229940066429 octoxynol Drugs 0.000 claims abstract 2
- 239000003921 oil Substances 0.000 claims abstract 2
- 239000003208 petroleum Substances 0.000 claims abstract 2
- 229920000136 polysorbate Polymers 0.000 claims abstract 2
- 229950008882 polysorbate Drugs 0.000 claims abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims abstract 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract 2
- 150000003871 sulfonates Chemical class 0.000 claims abstract 2
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Chemical class 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Chemical class 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 239000002280 amphoteric surfactant Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 239000003093 cationic surfactant Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2522/MUM/2010 | 2010-09-13 | ||
| IN2522MU2010 | 2010-09-13 | ||
| IN2539/MUM/2010 | 2010-09-14 | ||
| IN2539MU2010 | 2010-09-14 | ||
| PCT/GB2011/000785 WO2012035283A1 (en) | 2010-09-13 | 2011-05-23 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013113752A true RU2013113752A (ru) | 2014-10-20 |
Family
ID=44169144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013113752/15A RU2013113752A (ru) | 2010-09-13 | 2011-05-23 | Фармацевтическая композиция |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130315988A1 (enExample) |
| EP (1) | EP2616044A1 (enExample) |
| JP (1) | JP2013537182A (enExample) |
| KR (1) | KR20140029356A (enExample) |
| CN (1) | CN103221032A (enExample) |
| AU (1) | AU2011303715A1 (enExample) |
| BR (1) | BR112013005772A2 (enExample) |
| CA (1) | CA2810598A1 (enExample) |
| MX (1) | MX2013002802A (enExample) |
| NZ (1) | NZ607935A (enExample) |
| RU (1) | RU2013113752A (enExample) |
| WO (1) | WO2012035283A1 (enExample) |
| ZA (1) | ZA201301920B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| GB201306980D0 (en) * | 2013-04-17 | 2013-05-29 | Blueberry Therapeutics Ltd | Methods |
| WO2015140569A1 (en) * | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
| AU2015260837B2 (en) | 2014-05-12 | 2019-02-28 | Alfasigma S.P.A. | New solvated crystal form of rifaximin, production, compositions and uses thereof |
| WO2016014437A1 (en) * | 2014-07-21 | 2016-01-28 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
| ES2979135T3 (es) | 2016-10-14 | 2024-09-24 | Cipla Ltd | Composiciones farmacéuticas que comprenden rifaximina |
| WO2020219406A1 (en) * | 2019-04-22 | 2020-10-29 | Mylan Specialty L.P. | Meloxicam co-crystal compositions |
| MX427410B (es) | 2019-09-24 | 2025-10-13 | Bausch Health Ireland Ltd | Formulaciones liquidas de rifaximina |
| CA3184054A1 (en) | 2020-06-26 | 2021-12-30 | Jacob Cole | Targeted release rifaximin compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| WO2007047253A2 (en) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| CN100490790C (zh) * | 2007-04-28 | 2009-05-27 | 杭州民生药业集团有限公司 | 一种奥美拉唑肠溶微丸胶囊及其制备方法 |
| JP5755878B2 (ja) * | 2007-07-06 | 2015-07-29 | ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | リファキシミンの薬剤組成物 |
| JP2009137922A (ja) * | 2007-11-16 | 2009-06-25 | Kaneka Corp | リファマイシン誘導体を傷害組織にデリバリーする製剤 |
| US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| US8916193B2 (en) | 2008-12-10 | 2014-12-23 | Cipla Limited | Rifaximin complexes |
-
2011
- 2011-05-23 CN CN201180054627XA patent/CN103221032A/zh active Pending
- 2011-05-23 EP EP11724702.3A patent/EP2616044A1/en not_active Withdrawn
- 2011-05-23 US US13/822,478 patent/US20130315988A1/en not_active Abandoned
- 2011-05-23 RU RU2013113752/15A patent/RU2013113752A/ru not_active Application Discontinuation
- 2011-05-23 BR BR112013005772A patent/BR112013005772A2/pt not_active IP Right Cessation
- 2011-05-23 AU AU2011303715A patent/AU2011303715A1/en not_active Abandoned
- 2011-05-23 NZ NZ607935A patent/NZ607935A/en not_active IP Right Cessation
- 2011-05-23 KR KR1020137007569A patent/KR20140029356A/ko not_active Withdrawn
- 2011-05-23 JP JP2013527670A patent/JP2013537182A/ja not_active Ceased
- 2011-05-23 CA CA2810598A patent/CA2810598A1/en not_active Abandoned
- 2011-05-23 WO PCT/GB2011/000785 patent/WO2012035283A1/en not_active Ceased
- 2011-05-23 MX MX2013002802A patent/MX2013002802A/es not_active Application Discontinuation
-
2013
- 2013-03-12 ZA ZA2013/01920A patent/ZA201301920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201301920B (en) | 2013-10-30 |
| CN103221032A (zh) | 2013-07-24 |
| MX2013002802A (es) | 2013-06-03 |
| WO2012035283A1 (en) | 2012-03-22 |
| EP2616044A1 (en) | 2013-07-24 |
| AU2011303715A1 (en) | 2013-04-04 |
| NZ607935A (en) | 2015-01-30 |
| BR112013005772A2 (pt) | 2019-09-24 |
| KR20140029356A (ko) | 2014-03-10 |
| CA2810598A1 (en) | 2012-03-22 |
| WO2012035283A8 (en) | 2013-08-22 |
| JP2013537182A (ja) | 2013-09-30 |
| US20130315988A1 (en) | 2013-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537182A5 (enExample) | ||
| RU2012149115A (ru) | Фармацевтическая композиция | |
| CN101686972B (zh) | 治疗用组合物和方法 | |
| AU2010209790B2 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| JP2011006450A5 (enExample) | ||
| US9867801B2 (en) | Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same | |
| JP2018514534A5 (enExample) | ||
| JP2013545752A5 (enExample) | ||
| RU2016126430A (ru) | Пероральная фармацевтическая композиция | |
| JP2016518398A (ja) | 低用量医薬組成物 | |
| RU2707748C2 (ru) | Композиция водной суспензии, включающая наночастицы макролидных антибиотиков | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| EP1651218A1 (en) | Fexofenadine composition and process for preparing | |
| US20170368031A1 (en) | Solid dispersion formulations of antiviral compounds | |
| WO2012011882A1 (en) | A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases | |
| JP2019511465A5 (enExample) | ||
| US20180228826A1 (en) | Fixed-dose combinations of antiviral compounds | |
| KR101722432B1 (ko) | 류마티스성 관절염 등 자가면역 질환 치료의 개선방법 | |
| US20160346289A1 (en) | Fixed-Dose Combinations of Antiviral Compounds | |
| CN101862325B (zh) | 一种含有坎地沙坦酯的药物组合物 | |
| CN112533608B (zh) | 包含1,3,5-三嗪衍生物或其盐的固体药物组合物 | |
| CN106727382A (zh) | 一种卡维地洛过饱和自微乳分散片及其制备方法 | |
| CN102120030B (zh) | 一种艾普拉唑化学结构的药物及其用途 | |
| CN109419778B (zh) | 一种利伐沙班片剂及其制备方法 | |
| WO2021234554A2 (en) | Novel composition for the treatment of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160219 |